HDAC9 and idiopathic pulmonary fibrosis: Since epigenetic mechanisms have been implicated in IPF [10–12] and we have shown that the HDAC inhibitor SpA has powerful anti-fibrotic effects [17], here we report the potential of romidepsin as a candidate therapy for IPF.